GlaxoSmithKline Pharmaceuticals Limited - Laporan Laba Rugi (TTM)

GlaxoSmithKline Pharmaceuticals Limited
IN ˙ BSE ˙ INE159A01016
₹ 2,959.45 ↑55.00 (1.89%)
2025-04-30
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi GlaxoSmithKline Pharmaceuticals Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 30,823 31,609 29,256 33,403 34,708 34,861 32,780 33,048 32,875 32,739 32,517 32,683 33,084 33,114 34,537 35,067 35,605 37,046 37,492 37,397
Change (%) 2.55 -7.44 14.17 3.91 0.44 -5.97 0.82 -0.52 -0.41 -0.68 0.51 1.23 0.09 4.30 1.53 1.53 4.05 1.20 -0.25
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 12,491 12,726 12,824 13,870 14,226 14,048 13,782 13,690 13,455 13,135 13,041 13,133 13,027 13,314 13,552 13,544 13,844 14,267 14,139 14,063
Change (%) 1.88 0.76 8.16 2.57 -1.25 -1.89 -0.67 -1.72 -2.38 -0.71 0.71 -0.81 2.21 1.78 -0.06 2.22 3.06 -0.90 -0.53
% of Revenue 40.53 40.26 43.83 41.52 40.99 40.30 42.04 41.43 40.93 40.12 40.11 40.18 39.37 40.21 39.24 38.62 38.88 38.51 37.71 37.60
Gross Operating Profit 18,332 18,883 16,432 19,533 20,482 20,813 18,998 19,357 19,420 19,604 19,476 19,549 20,057 19,799 20,985 21,523 21,761 22,779 23,354 23,334
Change (%) 3.01 -12.98 18.87 4.86 1.62 -8.72 1.89 0.32 0.95 -0.65 0.38 2.60 -1.29 5.99 2.57 1.10 4.68 2.52 -0.08
% of Revenue 59.47 59.74 56.17 58.48 59.01 59.70 57.96 58.57 59.07 59.88 59.89 59.82 60.63 59.79 60.76 61.38 61.12 61.49 62.29 62.40
SG&A 7,598 7,523 6,858 7,629 7,689 7,521 7,397 7,238 7,057 7,163 7,062 7,200 7,233 7,116 7,358 7,220 7,275 7,109 7,018 7,031
Change (%) -0.98 -8.84 11.24 0.79 -2.19 -1.65 -2.15 -2.50 1.50 -1.41 1.95 0.45 -1.61 3.39 -1.86 0.76 -2.28 -1.28 0.18
% of Revenue 24.65 23.80 23.44 22.84 22.15 21.57 22.57 21.90 21.47 21.88 21.72 22.03 21.86 21.49 21.30 20.59 20.43 19.19 18.72 18.80
R&D
Change (%)
% of Revenue
OpEx 25,372 25,341 24,060 26,825 27,370 27,167 25,792 25,880 25,689 25,229 25,033 25,254 25,347 25,490 26,147 25,811 26,014 26,734 26,349 26,038
Change (%) -0.12 -5.05 11.49 2.03 -0.74 -5.06 0.34 -0.74 -1.79 -0.78 0.88 0.37 0.56 2.58 -1.29 0.79 2.77 -1.44 -1.18
% of Revenue 82.32 80.17 82.24 80.31 78.86 77.93 78.68 78.31 78.14 77.06 76.98 77.27 76.62 76.98 75.71 73.60 73.06 72.16 70.28 69.63
Operating Income 5,451 6,268 5,196 6,578 7,338 7,694 6,988 7,168 7,186 7,510 7,484 7,428 7,737 7,623 8,390 9,256 9,591 10,313 11,144 11,359
Change (%) 15.00 -17.11 26.59 11.56 4.85 -9.17 2.56 0.26 4.50 -0.34 -0.75 4.15 -1.47 10.06 10.32 3.62 7.52 8.06 1.93
% of Revenue 17.68 19.83 17.76 19.69 21.14 22.07 21.32 21.69 21.86 22.94 23.02 22.73 23.38 23.02 24.29 26.40 26.94 27.84 29.72 30.37
Interest Expense -64 -44 -35 -32 -27 -24 -20 -19 -19 -14 -18 -14 -15 -17 -18 -19 -17 -15 -13 -14
Change (%) -31.65 -19.84 -8.21 -16.35 -13.28 -15.11 -5.51 2.12 -25.44 26.19 -22.07 2.83 15.84 6.93 5.00 -8.47 -13.30 -12.34 3.81
% of Revenue -0.21 -0.14 -0.12 -0.10 -0.08 -0.07 -0.06 -0.06 -0.06 -0.04 -0.06 -0.04 -0.04 -0.05 -0.05 -0.05 -0.05 -0.04 -0.04 -0.04
Net Income -3,358 4,819 3,581 3,684 4,962 4,900 16,947 16,929 16,821 16,963 6,107 6,237 6,477 5,289 5,900 6,400 6,750 8,592 9,276 9,503
Change (%) -243.51 -25.68 2.86 34.68 -1.24 245.86 -0.11 -0.64 0.84 -64.00 2.12 3.86 -18.35 11.54 8.49 5.47 27.28 7.96 2.45
% of Revenue -10.89 15.25 12.24 11.03 14.30 14.06 51.70 51.23 51.17 51.81 18.78 19.08 19.58 15.97 17.08 18.25 18.96 23.19 24.74 25.41

Source: Capital IQ

Other Listings
IN:GLAXO ₹ 2,770.30
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista